The upstart pharmaceuticals developer has also reached a $100 billion market cap as a result of their nearly round-the-clock efforts in developing their mRNA-based coronavirus vaccine. But it seems this only set the scene for even more monumental challenges in the future, as the firm turns its focus toward one of the great scourges of mankind, cancer, as well as HIV, the Zika Virus, and influenza.
As of one year ago, Moderna had exactly zero marketed products using a completely unproven technology. Nothing it had ever produced had completed a large-scale clinical trial.
The new mRNA vaccines deliver a genetic code, informing cells how to make the virus proteins that provoke an immune response to Covid-19; from that point onward, our own bodies’ cells take on that mission.
